Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: MediciNova Clear all
Completed Phase 2 Interventional Results available

Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

NCT00679263
View directory record Official record
Conditions
Asthma
Interventions
MN-221, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Lenexa, Kansas • North Dartmouth, Massachusetts • Rolla, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Oct 2, 2026, 9:15 AM EDT
No Longer Available No phase listed Expanded access

Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

NCT06743776
View directory record Official record
Conditions
ALS
Interventions
MN-166
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
U.S. locations
15
States / cities
Scottsdale, Arizona • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Ibudilast for the Treatment of Alcohol Use Disorder

NCT03594435
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Ibudilast, Placebo oral capsule
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 1 Interventional

Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01013142
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
MN-221 (Dose Group 1), MN-221 (Dose Group 2), MN-221 (Dose Group 3)
Drug
Lead sponsor
MediciNova
Industry
Eligibility
40 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Fullerton, California • Tamarac, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis

NCT01982942
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions
ibudilast, Placebo oral capsule
Drug
Lead sponsor
MediciNova
Industry
Eligibility
21 Years to 65 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
28
States / cities
Birmingham, Alabama • Davis, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma

NCT03782415
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, GBM, Newly Diagnosed Glioblastoma
Interventions
MN-166, Temozolomide
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 1 Interventional

Safety Interaction Trial Ibudilast and Methamphetamine

NCT01217970
View directory record Official record
Conditions
Methamphetamine-dependence, Substance Abuse
Interventions
Ibudilast 20mg, Ibudilast 50mg, Placebo oral tablet
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT02238626
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo (for MN-166), MN-166, riluzole
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)

NCT02714036
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ibudilast
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Patchogue, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis

NCT02503657
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, IPF
Interventions
MN-001, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

NCT00295854
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
MN-001 BID, MN-001, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
28
States / cities
Birmingham, Alabama • Glendora, California • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

NCT04429555
View directory record Official record
Conditions
Pneumonia, Viral
Interventions
Ibudilast, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Denver, Colorado • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers

NCT03533387
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MN-166
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

NCT02681055
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease, Hypercholesterolemia
Interventions
MN-001
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Coronado, California • La Jolla, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 2, 2026, 9:15 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

NCT04057898
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
MN-166, placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
10
States / cities
Orange, California • Jacksonville, Florida • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 2, 2026, 9:15 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma

NCT00683449
View directory record Official record
Conditions
Asthma, Status Asthmaticus
Interventions
Dose Group 1, MN-221 placebo, Dose Group 2, Dose Group 3
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Sylmar, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 2, 2026, 9:15 AM EDT
Active, not recruiting Phase 2 Interventional

MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

NCT05464784
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
Interventions
MN-001, MN-001 placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
21 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Las Vegas, Nevada • Edinburg, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers

NCT01740414
View directory record Official record
Conditions
Opioid Abuse, Opioid Dependence
Interventions
MN-166 (50 mg) First, Placebo First
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 1 Interventional

Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01551316
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
MN-221, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
40 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
New Braunfels, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers

NCT04054206
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MN-166
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

NCT00838591
View directory record Official record
Conditions
Asthma
Interventions
MN-221, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Loma Linda, California • San Diego, California • Sylmar, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 2, 2026, 9:15 AM EDT